Neuromuscular Platforms for Drug Discovery
Designing and validating models for the study of neurological diseases presents a unique set of challenges. Experts understand that modeling neurodegenerative diseases may be arduous and can present challenges that need to be addressed when used for preclinical studies (Lutz & Osborne, 2013). In this whitepaper, we will review best practices for using models for neuromuscular diseases to identify molecular targets and to evaluate the efficacy of potential therapeutics.
Request a PDF copy